Results 61 to 70 of about 321,312 (283)

Safety and preliminary efficacy of vorinostat with R-EPOCH in high-risk HIV-associated non-Hodgkin\u27s lymphoma (AMC-075) [PDF]

, 2018
We performed a phase I trial of vorinostat (VOR) given on days 1 to 5 with R-EPOCH (rituximab plus etoposide, prednisone, vincristine, cyclophosphamide, and doxorubicin hydrochloride) in patients with aggressive HIV-associated non-Hodgkin lymphoma.
Aboulafia, David, Ambinder, Richard F, Cesarman, Ethel, Henry, David, Lee, Jeanette Y, Mitsuyasu, Ronald, Moore, Page C, Noy, Ariela, Ramos, Juan C, Ratner, Lee, Reid, Erin G, Rudek, Michelle A, Sparano, Joseph A   +12 more
core   +2 more sources

Tetrastigma Hemsleyanum Polysaccharide Suppresses Triple‐Negative Breast Cancer by Disrupting the Hippo‐YAP/TEAD4‐PDIA4 Axis and Endoplasmic Reticulum Stress Adaptation

Advanced Science, EarlyView.
ABSTRACT Triple‐negative breast cancer (TNBC) exhibits addiction to chronic endoplasmic reticulum (ER) stress, which sustains an aggressive metastatic phenotype through activation of the unfolded protein response (UPR). Here, we identify a previously unrecognized “ER‐stress addiction” axis in which the Hippo pathway effector TEAD4 directly ...
Yini Shang, Wentao Si, Youxue Zhang, Jialin Liu, Huaixi Zhang, Yafei Li, Hongmeng Su, Wei Jiang, Zhishan Ding, Lihong Wang   +9 more
wiley   +1 more source

Monoclonal Antibody: A New Treatment Strategy against Multiple Myeloma

Antibodies, 2017
2015 was a groundbreaking year for the multiple myeloma community partly due to the breakthrough approval of the first two monoclonal antibodies in the treatment for patients with relapsed and refractory disease. Despite early disappointments, monoclonal
Shih-Feng Cho, Liang Lin, Lijie Xing, Tengteng Yu, Kenneth Wen, Kenneth C. Anderson, Yu-Tzu Tai   +6 more
doaj   +1 more source

The antibody drug conjugate VLS-101 targeting ROR1 is effective in CAR T-resistant mantle cell lymphoma

Journal of Hematology & Oncology, 2021
Mantle cell lymphoma (MCL) is a rare, aggressive and incurable subtype of non-Hodgkin’s B-cell lymphoma. The principal barrier is frequent clinical relapse to multiple lines of therapies, including new FDA-approved biologics and cell therapy ...
Vivian Changying Jiang, Yang Liu, Alexa Jordan, Joseph McIntosh, Yijing Li, Yuxuan Che, Katti A. Jessen, Brian J. Lannutti, Michael Wang   +8 more
doaj   +1 more source

DENDRITIC CELL DIFFERENTIATION BLOCKED BY PRIMARY EFFUSION LYMPHOMA-RELEASED FACTORS IS PARTIALLY RESTORED BY INHIBITION OF P38 MAPK [PDF]

, 2010
To better understand the molecular mechanisms underlying the dendritic cell (DC) defects in cancer, we analyzed which signaling pathway is implicated in the abnormal monocyte differentiation into DC determined by the presence of Primary effusion lymphoma
CIRONE, Mara, DI RENZO, Livia Maria, FAGGIONI, Alberto, FRATI, Luigi, G. Borgia, G. Lucania, TRIVEDI, PANKAJ   +6 more
core   +2 more sources

Development and Structural Characterization of UTE‐156, a Covalent Inhibitor of the VCP/p97 AAA+ ATPase

Advanced Science, EarlyView.
The AAA+ ATPase Valosin‐containing protein (VCP/p97) regulates protein homeostasis by unfolding ubiquitinated substrates. Here, we describe UTE‐156, a novel irreversible covalent inhibitor that modifies Cys522 in the D2 ATPase motor domain. Although its pharmacochemical limitations preclude immediate therapeutic use, UTE‐156 serves as a valuable ...
Daniela Tamayo‐Jaramillo, Subramanya Hegde, Xuan Jia, Kimberly Coffman, Hariprasad Vankayalapati, David Bearss, Kevin B. Jones, Alex W. Stark, Peter S. Shen   +8 more
wiley   +1 more source

Tocilizumab prophylaxis for patients with multiple myeloma treated with bispecific antibodies

Blood Advances
: Bispecific antibodies for treatment for multiple myeloma are highly effective but commonly cause cytokine release syndrome (CRS) and immune effector cell–associated neurotoxicity syndrome (ICANS).
Andrew Kowalski, Jill Lykon, Benjamin Diamond, David Coffey, Marcella Kaddoura, Francesco Maura, James Hoffman, Abhishek Pandey, Dickran Kazandjian, Ola Landgren   +9 more
doaj   +1 more source

Enhancement of platelet response to immune complexes and IgG aggregates by lipid A-rich bacterial lipopolysaccharides. [PDF]

, 1978
The effect of the common lipid moiety of bacterial LPS on secretion from washed human platelets has been studied. The lipid A-rich LPS of S. minnesota R595 and a lipid A preparation both potentiated platelet serotonin secretion in response to IgG ...
Ginsberg, MH, Henson, PM
core   +1 more source

T Cell Exhaustion in Cancer Immunotherapy: Heterogeneity, Mechanisms, and Therapeutic Opportunities

Advanced Science, EarlyView.
T cell exhaustion limits immunotherapy efficacy. This article delineates its progression from stem‐like to terminally exhausted states, governed by persistent antigen, transcription factors, epigenetics, and metabolism. It maps the exhaustion landscape in the TME and proposes integrated reversal strategies, providing a translational roadmap to overcome
Yang Yu, Xiaoyu Yao, Qingyang Wang, Mengrui Yang, Runze Li, Jiangjiang Qin, Jing Zhuang, Changgang Sun   +7 more
wiley   +1 more source

Immune Checkpoint Inhibitors and Immunomodulators for Cancer Immunotherapy: Insights Into Resistance and Therapeutic Strategies

Advanced Science, EarlyView.
The schematic diagram illustrates the roles of novel immune checkpoints, immunomodulatory factors, cell death and multimodal technologies in cancer immunotherapy. Abstract Cancer immunotherapy has redefined cancer treatment. However, the molecular and cellular basis of immune evasion and therapeutic resistance remains incompletely understood.
Fangquan Chen, Yang Yu, Xiutao Cai, Junhao Lin, Ruirui Liang, Rui Kang, Daolin Tang, Jiao Liu   +7 more
wiley   +1 more source